SIC
TCRR

Salem Investment Counselors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Salem Investment Counselors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35
Closed -$53 – 1207
2023
Q1 		$53 Hold
35
– – ﹤0.01% 1105
2022
Q4 		$35 Hold
35
– – ﹤0.01% 1083
2022
Q3 		$0 Hold
35
– – ﹤0.01% 1152
2022
Q2 		$0 Hold
35
– – ﹤0.01% 1146
2022
Q1 		$0 Hold
35
– – ﹤0.01% 1143
2021
Q4 		$0 Hold
35
– – ﹤0.01% 1130
2021
Q3 		$0 Hold
35
– – ﹤0.01% 1042
2021
Q2 		$1K Buy
+35
New +$707 ﹤0.01% 883

Salem Investment Counselors's TCRR Position: Q2 2023 in Review

Salem Investment Counselors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 35 shares — an estimated $53 sold.

Salem Investment Counselors first reported a position in TCRR in Q2 2021 and held it in 8 quarters. The position peaked at $1K in Q2 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • Salem Investment Counselors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Salem Investment Counselors sold 35 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $53.
  • Salem Investment Counselors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • Salem Investment Counselors's TCR2 Therapeutics Inc. Common Stock position peaked at $1K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Salem Investment Counselors's 13F filing for Q2 2023, filed 19 Jul 2023.